Haemate P in children with von Willebrand's disease.
In our center, 289 children with von Willebrand's disease (vWD) have been diagnosed since 1982. The majority of cases (n = 198) were congenital vWD whereas 91 patients suffered from vWD induced by valproate (VPA). We overview bleeding episodes in 45 children and 64 operative procedures requiring therapeutic intervention. The aim of therapeutic and prophylactic procedures in vWD is correcting the hemostatic disorder and normalization of bleeding time. This can be achieved by application of Haemate P leading to an elevation of plasma levels of von Willebrand parameters together with normalization of bleeding time. In patients with vWD type I, DDAVP will be preferred if contraindications can be excluded and efficacy has been shown. Severe bleeding complications could be prevented in a total of 50 surgical procedures in children with vWD type I by prophylactic treatment with DDAVP or Haemate P. Two children initially treated with DDAVP had to be substituted with Haemate P in the follow-up because of continuous bleeding. In type IIa and type III vWD as well as in VPA-induced vWD, the use of Haemate P was essential for sufficient hemostasis in all bleeding and operations. We conclude that Haemate P provides effective bleeding prophylaxis and treatment in all types of vWD except platelet-type.
Kreuz
W
W
Center of Pediatrics, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany.
Mentzer
D
D
Becker
S
S
Scharrer
I
I
Kornhuber
B
B
D002648:Child; D000075202:Contraindications; D003894:Deamino Arginine Vasopressin; D005169:Factor VIII / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D012189:Retrospective Studies; D014842:von Willebrand Diseases / Q000188:drug therapy*
D005169:Factor VIII; D003894:Deamino Arginine Vasopressin